2.00

5.30

DAIDS Martin Delaney Collaboratory satellite workshop

2.00

3.30

Welcome and Highlights from Martin Delaney Collaboratory Leaders

DefeatHIV (Delaney Cell and Genome Engineering Initiative)

Keith Jerome, Fred Hutchinson Cancer Research Center, Seattle, WA, USA

CARE (Collaboratory of AIDS Researchers for Eradication)

David Margolis, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA

DARE (Delaney AIDS Research Enterprise)

Steven Deeks, University of California San Francisco, San Francisco, CA, USA

4.00

5.30

Panel Discussions: Cross-Cutting Challenges in Cure Research

1. Industry Partnerships and Overcoming Barriers to Translational Research

Chair: John Mellors, University of Pittsburgh, Pittsburgh, PA, USA

Lynda Dee, CARE CAB/AIDS Action Baltimore, Baltimore, MD, USA

David Evans, DARE CAB/Project Inform, San Francisco, CA, USA

Romas Geleziunas, Gilead Sciences, Inc., Foster City, CA, USA

Bonnie Howell, Merck & Co., West Point, PA, USA

Jonathan Karn, Case Western Reserve University, Cleveland, OH, USA

David Margolis, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA

2. ARVs and Optimizing Animal Models for Evaluation of HIV Cure Strategies

Chair: Guido Silvestri, Emory University, Atlanta, GA, USA

Janice Clements, Johns Hopkins University School of Medicine, Baltimore, MD, USA

J. Victor Garcia, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA

Hans-Peter Kiem, Fred Hutchinson Cancer Research Center, Seattle, WA, USA

Jeff Lifson, National Cancer Institute, Frederick, MD, USA

Jeff Taylor, CARE CAB/AIDS Treatment Activists Coalition, Palm Springs, CA, USA

3.Clinical Trial Design: Appropriate Populations and Endpoints for Control vs. Eradication Studies

Chair: Jintanat Ananworanich, US Military HIV Research Program, Bethesda, MD, USA

Steven Deeks, University of California San Francisco, San Francisco, CA, USA

Daniel Kuritzkes, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, USA

Sharon Lewin, Doherty Institute, University of Melbourne, Melbourne, Australia

Timothy Schacker, University of Minnesota, Minneapolis, MN, USA

Matthew Sharp, MDC CAB Coordinator, San Francisco, CA, USA

Laurie Sylla, defeatHIV CAB, Seattle, WA, USA

5.30

Introduction Mario Stevenson, University of Miami Leonard School of Medecine, Miami - USA

5.40

7.00

Opening Ceremony

Carl Dieffenbach, Director of the NIAID, Division of AIDS, Bethesda - USA

Introduced by Karl Salzwedel, NIAID, Division of AIDS, Bethesda - USA

7.00

Welcome dinner

8.00

10.00

SESSION 1: In vitro and in vivo models of HIV persistence

Chairs: David Margolis, University of North Carolina, Chapel Hill - USA

Christian Schwartz, Institute of Parasitology and Tropical Diseases, Strasbourg - FRA

 OP 1.0 HIV Persistence: to the periphery and beyond

Author: J. Victor Garcia Martinez, Div. of Infectious Diseases/UNC CFAR,

University of North Carolina at Chapel Hill, Chapel Hill, NC, United States of America

 OP 1.1 Clones of SIV Infected Cells Are Present in Spleen and Lymph Nodes in Rhesus Macaques

Authors: S. H. Hughes1, A. L. Ferris1, G. Q. Del Prete2, B. F. Keele2, X. Wu3, J. D. Lifson2

1 HIV Dynamics and Replication Program, NCI- Frederick, Frederick, MD, United States of America

2 Aids and Cancer Virus Program, Leidos Biomedical Research, Inc, Frederick, MD, United States of America

3 Laboratory of Molecular Technology, Leidos Biomedical Research, Inc, Frederick, MD,

United States of America

 OP 1.2 Evaluation of HIV latency reversal using designed PKC modulators in humanized BLT mice

Authors: M.D. Marsden1, X. Wu1, B.A. Loy2, B.A. DeChristopher2, A.J. Schrier2, C.M.R. Kitchen1, E. Beans2,

D. Fournogerakis2, C. Gauntlett2, L. Heumann2, R. Kramer2, D. Murray3, T.W. Chun3, P.A. Wender2, J.A. Zack1.

1 UCLA, Los Angeles, CA, United States of America

2 Stanford University, Stanford, CA, United States of America

3 National Institute of Allergy and Infectious Diseases, Bethesda, Maryland, United States of America

 OP 1.3 Shining the RNA-Seq Microscope on Models of HIV Latency

Authors: C.H. Woelk 4**, C.H. White1,2,*, A. Bosque3,*, B. Moesker4, C.A. Spina1,5, D.D. Richman1,2,5,

N. Beliakova-Bethell1,5 and V. Planelles3,**

1 VA San Diego Healthcare System, San Diego, CA, United States of America

2 Department of Pathology, University of California San Diego, La Jolla, CA, United States of America

3 School of Medicine, University of Utah, Salt Lake City, UT, United States of America

4 Faculty of Medicine, University of Southampton, Southampton, Hants, United Kingdom

5 Department of Medicine, University of California San Diego, La Jolla, CA, United States of America

* First authors contributed equally to this abstract.

**Senior authors contributed equally to this abstract.

 OP 1.4 In vivo suppression of SIV-mediated immune activation by a p38 MAPK inhibitor combined with ART

Authors: A. Aldovini1, O. Chaudhary1, V. Narayan1 and R. Veazey2

1 Boston Children’s Hospital, Department of Medicine and Harvard Medical School, Department of Pediatrics,

Boston MA, United States of America

2 Tulane Primate Research Center, Tulane University, Covington, LA, United States of America

 OP 1.5 Memory CD4+ T cell subsets show differential responses to HIV latency reversing agents

Authors: D.A. Kulpa1, S. Yuan2, A. Talla3, A. G. Bebein-Blackwell4, J. Brehm5, R. Barnard6, M. Miller6,

D. Hazuda6, N. Chomont7, and R.P. Sékaly3

1 Southern Research Institute, Frederick, MD, United States of America

2 Janssen Pharmaceuticals, Springhouse, PA, United States of America

3 Case Western Reserve University, Cleveland, OH, United States of America

4 University of Georgia, Athens, GA, United States of America

5 GlaxoSmithKline, Raleigh, NC, United States of America

6 Merck, West Point, PA, United States of America of America

7 Université de Montréal, Montréal, QC, Canada

 OP 1.6 Quantifying the Impact of Autologous Transplantation on Viral Reservoirs

in a Nonhuman Primate Model of HIV/AIDS

Authors: C.W. Peterson1, C. Benne2, P. Polacino3, A. Baldessari4, R.D. Murnane4, S.L. Hu3, R. Sekaly2,

and H. Kiem1,3

1 Fred Hutchinson Cancer Research Center, Seattle, WA, United States of America

2 Case Western Reserve University, Cleveland, OH, United States of America

3 University of Washington, Seattle, WA, United States of America

4 Washington National Primate Research Center, Seattle, WA, United States of America

10.30

12.30

SESSION 2: Basic science of HIV latency

Chairs: Jonathan Karn, Case Western Reserve University, Cleveland - USA

John Coffin, Tufts University School of Medicine, Boston - USA

 OP 2.0 HIV-1 transcriptional latency in resting CD4 T-cell

Author: Jonathan Karn, Case Western Reserve University, Cleveland - USA

 OP 2.1 Single-cell analysis identifies biomarkers for HIV permissiveness

Authors: A. Ciuffi1*,S. Quenneville1*, A. Rausell1,2*, S. Rato1, M. Muñoz1 and A. Telenti3*

1 Institute of Microbiology, University of Lausanne, Lausanne, Switzerland

2 Vital-IT group, SIB Swiss Institute of Bioinformatics, Lausanne, Switzerland

3 J. Craig Venter Institute, La Jolla, CA, United States of America

 OP 2.2 Cellular HIV RNA/DNA as Biomarkers of Inducible Virion Production

Authors: A. Cillo1, F. Hong1, A. Tsai2, A. Irrinki2, J. Kaur2, J. Lalezari3, D. Sloan2, J. P. Murry2, J. Mellors1

1 University of Pittsburgh, Pittsburgh, PA, United States of America

2 Gilead Sciences, Foster City, CA, United States of America

3 Quest Clinical Research, San Francisco, CA, United States of America

 OP 2.3 The HIV-1 antisense transcript AST is an inducer of viral latency

Authors: F. Romerio1, J.C. Zapata1, F. Kashanchi2 and S. Iordanskyi2

1 Institute of Human Virology, Baltimore, MD, United States of America

2 George Mason University, Manassas, VA, United States of America

 OP 2.4 Integration Site Analysis of Latently Infected Cell Lines: Evidence of Ongoing Replication

Authors: J. Symons1,S.R. Lewin1,5, , A. Chopra2, E. Malantinkova3, W. De Spiegelaere3, S. Leary2, D. Cooper2,

L. Vandekerckhove3, S. Mallal2,4 and P. Cameron1,5

1 The Peter Doherty Institute for Infection and Immunity, The University of Melbourne, Melbourne, VIC,

Australia

2 Institute for Immunology and infectious diseases (IIID), Murdoch University, Perth, WA, Australia

3 HIV Translational Research Unit, Department of Internal Medicine, Faculty of Medicine and Health Sciences,

Ghent University and Ghent University Hospital, Ghent, Belgium

4 Dept of Infectious Diseases, Vanderbilt University Nashville, United States of America

5 Department of Infectious Diseases, Alfred Hospital and Monash University, Melbourne, Australia

 OP 2.5 Mixed effects of HDACi on host gene expression and their implications

for HIV reactivation from latency.

Authors: N. Beliakova-Bethell1,2, A. Mukim2, S. Deshmukh2, C. H. White3, C.H. Woelk4, C.A. Spina2,5

1 Department of Medicine, University of California San Diego, La Jolla, CA, United States of America

2 VA San Diego Healthcare System, San Diego, CA, United States of America

3 Graduate Program in Bioinformatics and Systems Biology, University of California San Diego, La Jolla,

CA, United States of America

4 Faculty of Medicine, University of Southampton, Southampton, Hants, United Kingdom

5 Department of Pathology, University of California San Diego, La Jolla, CA, United States of America

 OP 2.6 HIV-1 Latency is Established Preferentially in Minimally Activated and Non-Dividing Cells during Productive Infection of Primary CD4 T Cells

Authors: C.A. Spina1,2, P. C. Soto1,2, V. H. Terry1 and M.K. Lewinski3

1 Veterans Affairs San Diego Healthcare System, San Diego, CA, United States of America

2 Department of Pathology, University of California San Diego, La Jolla, CA, United States of America

3 Department of Medicine, University of California San Diego, La Jolla, CA, United States of America

4.00

5.30

SESSION 4: Anatomic and non-CD4 cell reservoirs

Chairs: Janice Clements, Johns Hopkins Medicine Institute, Baltimore - USA

Mario Stevenson, University of Miami Leonard School of Medicine, Miami - USA

 OP 4.0 Tissue localization of human T cell responses

Author: Donna Farber, Columbia University Medical Center, New York, NY, United States of America

 OP 4.1 Proliferation of perivascular macrophages in macaque models of lentiviral encephalitis:

a potential mechanism for HIV/SIV persistence in the brain

Authors: W.K. Kim , A.R. Filipowicz, C.M. McGary, G.E. Holder and M.J. Kuroda

Eastern Virginia Medical School, Norfolk, VA, United States of America

 OP 4.2 The human lung is a site of productive HIV infection during long term ART:

novel tools to study ART-durable HIV reservoirs

Authors: D.W. Gludish1, H.C. Mwandumba2, K.C. Jambo2, S. M. Amie1 and D.G. Russell1

1 Department of Microbiology and Immunology, College of Veterinary Medicine, Cornell University, Ithaca,

NY, United States of America

2 Malawi-Liverpool-Wellcome Trust Clinical Research Programme, University of Malawi, College of Medicine,

Blantyre, Malawi

 OP 4.3 Lymphatic and cancer tissues are a potential reservoir of replicating virus in virally suppressed ART+ patients

Authors: R. Rose1, S.L. Lamers1, D.J. Nolan1,2, M.S. McGrath3

1 Bioinfoexperts, LLC, Thibodaux, Los Angeles, CA, United States of America

2 Department of Pathology, Immunology, and Laboratory Medicine, Emerging Pathogens Institute, University

of Florida, Gainesville, FL, United States of America

3 The AIDS and Cancer Specimen Resource and the Department of Laboratory Medicine, Medicine and

Pathology, University of California at San Francisco, San Fransisco CA, United States of America

 OP 4.4 Immunological properties of testicular tissue as an anatomical reservoir in ART-treated HIV-infected adults

Authors: J.P. Routy2,6, M.A. Jenabian1, J. Brousseau1, K. Vyboh2, F.M. Ghazawi1,3, P. Brassard4, M. Bélanger4,

N. Chomont5 and P. Ancuta5

1 Department of Biological Sciences and BioMed Research Centre, Université du Québec à Montréal (UQAM), Canada

2 Chronic Viral Illness Service and Research Institute, McGill University Health Centre, Montréal, QC, Canada

3 Faculty of Medicine, McGill University, Montréal, QC, Canada

4 Metropolitan Centre for Plastic Surgery, Montréal, QC, Canada

5 Université de Montréal, Faculté de Médecine, Département of microbiologie, infectiologie et immunologie

and Centre de recherche du CHUM, Montréal, QC, Canada

6 Division of Hematology, McGill University Health Centre, Montréal, QC, Canada

 OP 4.5 Persistence of HIV-infected alveolar macrophages after suppressive ART

Authors: F.F. Hong, H. Michael, S. Qin, L.A. Kingsley, D. D. McMahon, M.E. Fitzpatrick, A.M. Morris and

J.W. Mellors - University of Pittsburgh, Pittsburgh, PA, United States of America

8.00

10.00

SESSION 5: Immunology of HIV persistence

Chairs: Nicolas Chomont, CHUM Research Center, Montréal - CAN

Marie-Lise Gougeon, Pasteur Institute, Paris - FRA

 OP 5.0 Immune control of HIV reservoirs and cure therapeutic strategies

Author: Nilu Goonetilleke, UNC, Chapel Hill - USA

 OP 5.1 Long-term Spontaneous control of HIV-1 relates to low frequency of infected cells

and inefficient viral reactivation

Authors: J.G. Prado5*,N. Noel 1,2,3,4, R. Peña5, A. David6, V. Avettand-Fenoel7,8, I. Erkizia5, E. Jimenez5, C.Lecuroux1,3,

C. Rouzioux 7,8, F. Boufassa9, G. Pancino10, A. Venet1, C. Van Lint11, J. Martinez-Picado5,12,13, O. Lambotte1,2,3,4,

A. Sáez-Cirión6* and for the ANRS CO21 Cohort

1 Université Paris Sud, UMR-1184, France

2 CEA, DSV/iMETI, Division of Immuno-Virology, IDMIT, France

3 Inserm, U1184, Center for immunology of viral infections and autoimmune diseases, France

4 APHP, Service de Médecine Interne & Immunologie Clinique, Hôpitaux Universitaires Paris Sud, le Kremlin

Bicêtre, France

5 AIDS Research Institute -IrsiCaixa-, Institut d’Investigació en Ciències de la Salut Germans Trias i Pujol,

Universitat Autónoma de Barcelona, Badalona, Spain

6 Institut Pasteur, Unité HIV Inflammation et Persistance, Paris, France

7 APHP, Hôpital Necker, Service de Virologie, Paris, France

8 Université Paris Descartes, Sorbonne Paris Cité, Faculté de Médecine, EA7327, Paris, France

9 INSERM U1018, Faculté de Médecine Paris Sud, Le Kremlin-Bicêtre, France

10 Institut Pasteur, Unité de Régulation des Infections Rétrovirales, Paris, France

11 Service de Virologie Moléculaire, IBMM, Université Libre de Bruxelles (ULB), Gosselies, Belgique

12 Universitat de Vic, Barcelona, Spain

13 Institució Catalana de Recerca i Estudis Avançats (ICREA), Barcelona, Spain

* Equal contributors

 OP 5.2 Differential Effects of HIV Latency Reversing Agents on T Cell Phenotype and Function: Implications for HIV Cure

Authors: G. Clutton, N. Archin, Y. Xu, D.M. Margolis, N. Goonetilleke - The University of North Carolina

at Chapel Hill, Chapel Hill, NC, United States of America

 OP 5.3 CD8+ sensing relies on nanomolar levels of antigen presented upon HIV-1 reactivation

Authors: A. Ruiz1, E. Jimenez1, R. Peña1, P. Goulder2, B. Clotet1 and J.G Prado1

1 AIDS Research Institute IrsiCaixa, Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona, Spain

2 Department of Pediatrics, University of Oxford, Oxford, United Kingdom

 OP 5.4 Long-Lived Th17 Subsets Contribute to HIV-1 Persistence under ART

Authors: V.S. Wacleche1,2, P. Ancuta1, 2,*, J.P. Goulet3, A. Gosselin2, P. Monteiro1,2, H. Soudeyns1,4, M.A. Jenabian5, S.G. Deeks6, N. Chomont1,2, and J.P. Routy7,8

1 Université de Montréal, Faculté de Médecine, Département of microbiologie, infectiologie et immunologie,

Montréal, QC, Canada

2 Centre de recherche du CHUM, Montréal, QC, Canada

3 Caprion, Montréal, QC, Canada

4 Unité d’immunopathologie virale, Centre de recherche du CHU Sainte-Justine, Montréal, QC, Canada

5 Département des sciences biologiques, Université du Québec, Montréal, QC, Canada

6 Department of Medicine, University of California San Francisco, San Francisco, CA, USA

7 Chronic Viral Illness Service and Research Institute, McGill University Health Centre, Montréal, QC, Canada

8 Division of Hematology, McGill University Health Centre, Montréal, QC, Canada

 OP 5.5 Uncovering mechanisms of HIV persistence in HIV controllers by HIV sequence analysis in CD4 T cell subsets

Authors: E. Boritz, S. Darko, F. Simonetti, D. Wells, X. Wu, L. Swaszek, G. Wolf, R. Hoh, A. Vostal, A. Ober, M. Hughes, D. Bunis, S. Migueles, J. Casazza, R. Koup, M. Connors, S. Moir, J. Martin, F. Maldarelli, S. Hughes,

S. Deeks and D. Douek - Vaccine Research Center, NIAID, Bethesda, United States of America

 OP 5.6 The Transcriptional Program Governed by RORgt Favors HIV-1 Replication in CCR4+CCR6+ Th17 Cells

Authors: V.S. Wacleche1,2 , A. Cleret-Buhot1,2, Y. Zhang 1,2, D. Planas1,2, J.P. Goulet3, P. Monteiro1,2, J. Niessl1,2,

A. Gosselin2, C. Tremblay1,2, M.A. Jenabian4, J.P. Routy5,6,7, M. El-Far2, N. Chomont1,2, E.K. Haddad8, R.P. Sekaly9, P. Ancuta1,2

1 Department of Microbiology, Infectiology and Immunology, Faculty of Medicine, Université de Montréal, Qc,

Canada

2 CHUM-Research Centre, Montréal, Qc, Canada

3 Caprion, Montréal, Qc, Canada

4 Département des sciences biologiques, Université du Québec, Montréal, Qc, Canada

5 Chronic Viral Illness Service, McGill University Health Centre, Montréal, QC, Canada

6 Research Institute, McGill University Health Centre, Montréal, QC, Canada

7 Division of Hematology, McGill University Health Centre, Montréal, QC, Canada

8 Drexel University, Division of infectious Diseases and HIV Medicine, Philadelphia, PA, United States of America

9 Case Western Reserve University, Center for AIDS Research, Cleveland, OH, United States of America

 OP 5.7 Latency reversing agents and cellular activation affect antigen processing in primary CD4 T cells

Authors: J. Boucau, J. Madouasse, D. Wambua, M.J. Berberich and S. Le Gall - The Ragon Institute of MGH,

MIT and Harvard, Cambridge, MA, United States of America

10.30

12.30

SESSION 6: Pharmacology of HIV persistence

Chairs: Guido Poli, San Raffaele University School of Medicine, Milano - ITA

Jean-Pierre Routy, McGill University, Montréal - CAN

 OP 6.0 A Pharmacologic Basis for HIV Persistence

Author: Courtney Fletcher, University of Nebraska Medical Center, Omaha – USA

 OP 6.1 A subset of infectious proviruses persist and expand following activation ex vivo

Authors: J.K. Bui1,2, E. Halvas1, E. Fyne1, M.D. Sobolewski1, D. Koontz1, M.F. Kearney3, W. Shao4, F.F. Hong1,

J.W. Mellors1

1 University of Pittsburgh, Department of Medicine, Pittsburgh, PA, United States of America

2 Howard Hughes Medical Institute, Medical Research Fellows Program, Bethesda, WA, United States of America

3 National Cancer Institute (NCI), HIV Dynamics and Replication Program, Frederick, MD,

United States of America

4 Leidos, Advanced Biomedical Computing Center, Frederick, MD, United States of America

 OP 6.2 Lymphoid Tissue and Blood CD4 T Cells Respond Differently to Latency-Reversing Agents: Are We Testing the Right Cells?

Authors: W.C. Greene, A. Gramatica and M. Montano - Gladstone Institute of Virology and Immunology

and the University of California, San Francisco, United States of America

 OP 6.3 Role of Drug Transporters and Metabolic Enzymes in Antiretroviral Drug (ARV) Disposition in Testicular Tissue-Potential Contribution to HIV-1 Persistence

Authors: R. Bendayan , Y. Huang, S.K. Whyte, Md. T. Hoque, M.A. Jenabian, K. Vyboh, N. Sheehan,

P. Brassard, M. Belanger, N. Chomont, C.V. Fletcher and J.P. Routy - University of Toronto,

Leslie Dan Faculty of Pharmacy, Toronto, Canada

8.00

10.00

SESSION 9: New therapeutic approaches 1

Chairs: José Gatell, University of Barcelona, Barcelona – SPA

Javier Martinez Picado, University Hospital “Germans Trias i Pujol”, Barcelona - SPA

 OP 9.0 Potential role for neutralizing antibodies in HIV-1 infection

Author: John Mascola, NIAID, Vaccine Research Center, Bethesda, MD, United States of America

 OP 9.1 Targeting HIV Reservoir by DART Molecules That Recruit T Cells to HIV Env Expressing Cells: Comparison of HIV Arms Derived from Broadly Reactive Neutralizing

or Non-Neutralizing Anti-Env Antibodies

Authors: J.L. Nordstrom1, D.D. Sloan2, C.Y. Kao Lam1, A. Irrinki2, L. Liu1, A. Tsai2, C.S. Pace2, J. Kaur2,

J.P. Murry2, M. Balakrishnan2, P.A. Moore1, S. Johnson1, T. Cihlar2 and S. Koenig1

1 MacroGenics, Inc., 9640 Medical Center Drive, Rockville, MD, United States of America

2 Gilead Sciences, 333 Lakeside Drive, Foster City, CA, United States of America

 OP 9.2 CL572, a Potent Agonist of Toll-like Receptor 2/7, as a Novel Latency Reversing Agent

Authors: A. Macedo1, C.M. Assis1, C.L. Novis1, A. Spivak2, V. Planelles1 and A. Bosque1

1 Department of Pathology, University of Utah, Salt Lake City, UT, United States of America

2 Department of Medicine, University of Utah, Salt Lake City, UT, United States of America

 OP 9.3 HIV Conserved Region Vaccine in Early cART-Treated Subjects (BCN01): Impact on immunogenicity and the latent reservoir

Authors: S. Morón-López1, B. Mothe1,2,3, C. Manzardo4, A. Sanchez-Bernabeu1, P. Coll1,2, M.C. Puertas1, L. Dorrell5, J.M. Miró2, B. Clotet1,2,3,6, C. Brander1,3,6,7, J. Martinez-Picado1,3,6,7 and T. Hanke8 for the BCN01 study group

1 IrsiCaixa AIDS Research Institute-HIVACAT, Badalona, Spain

2 Fundació Lluita contra la Sida, Hospital Universitari Germans Trias i Pujol, Badalona, Spain

3 Universitat de Vic-Central de Catalunya (UVic-UCC), 4Hospital Clinic-IDIBAPS, Barcelona, Spain

5 The John Radcliffe Hospital, Oxford, United Kingdom

6 Universitat Autònoma de Barcelona (UAB), Barcelona, Spain

7 ICREA, Barcelona, 8The Jenner Institute, University of Oxford, Oxford, United Kingdom

 OP 9.4 Antiviral therapy by targeting nanoparticles to CD4+ cells for the delivery

of SIV-specific RNA-guided Cas9 nucleases

Authors: L. Giavedoni2, L. Smith1,2, E. Carnes3,4, C. Lino4, V. Hodara2, K. Reimann5 and L. Parodi2

1 University of Texas Health Science Center, San Antonio, TX, United States of America

2 Texas Biomedical Research Institute, San Antonio, TX, United States of America

3 University of New Mexico, Albuquerque, NM, United States of America

4 Sandia National Laboratories, Albuquerque, NM, United States of America

5 University of Massachusetts Medical School, Boston, MA, United States of America

 OP 9.5 Potent CTL Responses to Conserved Element of HIV to Improve Therapeutic

DNA Vaccine Efficacy

Authors: B. K. Felber1, A. Valentin1, J.I. Mullins2, and G.N. Pavlakis1

1 National Cancer Institute at Frederick, Frederick, MD, United States of America

2 University of Washington, Seattle, WA, United States of America

 OP 9.6 Immune response to sequences surrounding the 12 protease cleavage sites generated during ARV treatment improved CD4 counts of SIVmac251 infected rhesus monkeys

Authors: M. Luo1,2, D. Tang1, J. Pinto3, M. Nykoluk1, P. Lacap1, Jeff Tuff1, R. Capina1, Chris Czarnecki1,

J. Whitney4, M. Alonso3, T. Ball2,5, G. Kobinger2,6, P. Sandstrom5 and F. Plummer2,7

1 National Microbiology Laboratory, HIV Host Genetics/NHRL, Winnipeg, Canada

2 University of Manitoba, Medical Microbiology, Winnipeg, Canada

3 University of Santiago de Compostela, Santiago de Compostela, Spain

4 Harvard Medical School, Beth Israel Deconess Medical Center, Boston, MA, United States of America

5 National Microbiology Laboratory, NHRL, Winnipeg, Canada

6 National Microbiology Laboratory, Special Pathogens, Winnipeg, Canada

7 National Microbiology Laboratory, Winnipeg, Canada

 OP 9.7 Elimination of HIV-1 Genomes from Human T-lymphoid Cells by CRISPR/Cas9 Gene Editing

Authors: K. Khalili1,2, R. Kaminski1,2, Y. Chen1,2, T. Fischer1,2, E. Tedaldi2,3, A. Napoli1,2, Y. Zhang1,2,

J. Karn4 and W. Hu1,2

1 Department of Neuroscience/Center for Neurovirology, Temple University School of Medicine,

Philadelphia, PA, United States of America

2 Comprehensive NeuroAIDS Center, Temple University School of Medicine, Philadelphia, PA, United

States

3 Department of Medicine, Temple HIV Program, Temple University School of Medicine, Philadelphia, PA,

United States of America

4 Department of Molecular Biology and Microbiology, Case Western Reserve University, Cleveland,

OH, United States of America

10.30

12.30

SESSION 10: New therapeutic approaches 2

Chairs: T. Mesplede, Jewish General Hospital, Montréal - CAN

Alain Lafeuillade, CHITS - Sainte Musse Hospital, Toulon - FRA

 OP 10.0 The anti-inflammatory response and the HIV Cure

Author: Rafick Sekaly, Case Western Reserve University, Cleveland, United States of America

 OP 10.1 Emergence of treatment-resistant infectious HIV after genome-directed antiviral endonuclease therapy

Authors: K.R. Jerome1, 2, 3, D. Stone1, H.S. De Silva Feelixge1, P. Roychoudhury1 and J.T. Schiffer1, 5

1 Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA, United States of America

2 Department of Laboratory Medicine, University of Washington, Seattle, WA, United States of America

3 Department of Microbiology, University of Washington, Seattle, WA, United States of America

4 Department of Biochemistry, University of Washington, Seattle, WA, United States of America

5 Department of Medicine, University of Washington, Seattle, WA, United States of America

 OP 10.2 The effects of combination of Ingenol-B and ART to SIV251 infected rhesus monkeys

Authors: G. dos Santos Goncalves1, D. O’Connor2, S. O’Connor2 and A. Tanuri1

1 Universidade Federal do Rio de Janeiro, Brazil

2 University of Wisconsin-Madison, Madison, WI, United States of America

 OP 10.3 Dendritic Cell induced “kick” of latent HIV-1 in vitro during cART

Authors: R.B. Mailliard1, J. Kristoff1, D. Ratner, M. Ding, J.M. Zerbato2, N.D. Sluis-Cremer2,

P. Gupta1 and C.R. Rinaldo1

1 Department of Infectious Diseases and Microbiology, University of Pittsburgh, Pittsburgh, PA,

United States of America

2 Division of Infectious Diseases, Department of Medicine, University of Pittsburgh School of Medicine,

Pittsburgh, PA, United States of America

 OP 10.4 Peripheral blood lymphocytes from patients with chronic myeloid leukemia on treatment with Dasatinib are resistant to HIV-1 infection

Authors: M. Coiras1, M. Bermejo1, J. García-Pérez1, J. Ambrosioni2, J.M. Miró2, M. Plana3 and J. Alcamí1

1 AIDS Immunopathology Unit, National Center of Microbiology, Instituto de Salud Carlos III, Madrid, Spain

2 Infectious Diseases Service, AIDS Research Group, Institut d´Investigacions Biomèdiques August Pi I Sunyer

(IDIBAPS), Hospital Clínic, University of Barcelona, Barcelona, Spain

3 Retrovirology and Viral Immunopathology Laboratory, AIDS Research Group, Institut d´Investigacions

Biomèdiques August Pi I Sunyer (IDIBAPS), Hospital Clínic, University of Barcelona, Barcelona, Spain

 OP 10.5 Restricted HIV-1 Diversity and Clonal Expansion Following Cytoreductive Chemotherapy

Authors: T.J. Henrich1,2, E.P. Scully3, K.S. Hobbs1,2, E. Hanhauser1,2, L.E. Hogan1,2, C.D. Palmer3, Y.P. Robles1, K.S. Leadabrand2, A.S. LaCasce4, D.R. Kuritzkes1

1 Brigham and Women’s Hospital, Boston, MA, United States of America

2 University of California San Francisco, San Francisco, CA, United States of America

3 Ragon Institute of MGH, MIT and Harvard, Boston, MA, United States of America

4 Dana-Farber Cancer Center, Boston, MA, United States of America

 OP 10.6 Dual-Affinity Re-Targeting (DART) proteins overcome viral diversity to deplete the latent HIV-1 Reservoir

Authors: J.M. Sung, J. Pickeral, M. Bednar, L. Liu, S.A. Stanfield-Oakley, J. Pollara, C. LaBranche, M.A. Moody, M. Bonsignori, C.Y. Kao Lam, S. Johnson, C. Garrido, N. Archin, J. Kuruc, M. Cohen, K. Soderberg, H.X. Liao, D. Montefiori, R. Swanstrom, S. Koenig, J. Nordstrom, B.F. Haynes, G. Ferrari, D. Margolis – UNC Chapel Hill, Chapel Hill, United States of America

 OP 10.7 Human Galectin-9 is a Potent Mediator of HIV Transcription and Reactivation

Authors: M. Abdel-Mohsen1,2, L. Chavez1, G. M. Chew3, X. Deng1, A. Danesh1,2, S. Keating1, R. Hoh2,

S.G. Deeks2, L.C. Ndhlovu3 and S.K. Pillai1,2

1 Blood Systems Research Institute, San Francisco, CA, United States of America

2 University of California, San Francisco, United States of America

3 University of Hawaii, Hawaii Center for AIDS, John A. Burns School of Medicine,

Honolulu, HI, United States of America